chf.jpg
CHF Solutions’ Physician-Led Webinar Highlights Real-World Evidence Supporting Effectiveness of Ultrafiltration in Heart Failure Patients
28 janv. 2021 08h00 HE | CHF Solutions, Inc.
EDEN PRAIRIE, Minn., Jan. 28, 2021 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today...
chf.jpg
CHF Solutions Offers Educational Event on Effective Fluid Management Strategies in Heart Failure Patients
21 janv. 2021 08h00 HE | CHF Solutions, Inc.
EDEN PRAIRIE, Minn., Jan. 21, 2021 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today...
CVRx® Appoints New Chief Marketing Officer and Vice President of European Sales and Marketing
05 janv. 2021 10h55 HE | CVRx, Inc.
MINNEAPOLIS, Jan. 05, 2021 (GLOBE NEWSWIRE) -- CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announced that it is expanding...
BioCardia-Final-Logo-2016-JPEG.jpg
BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Heart Failure Study as Designed
17 déc. 2020 08h30 HE | BioCardia, Inc.
SAN CARLOS, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) -- BioCardia (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that...
chf.jpg
CHF Solutions Announces Meta-Analysis Demonstrates Ultrafiltration is Better than Diuretic Therapy for the Management of Volume Overload in ADHF
15 déc. 2020 08h00 HE | CHF Solutions, Inc.
EDEN PRAIRIE, Minn., Dec. 15, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today...
22157.jpg
Global Atrial Fibrillation Treatment Market (2020 to 2025) - Industry Trends, Share, Size, Growth, Opportunity and Forecast
10 déc. 2020 04h13 HE | Research and Markets
Dublin, Dec. 10, 2020 (GLOBE NEWSWIRE) -- The "Atrial Fibrillation Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to...
54741_Image_jpeg.jpg
Daxor Corporation to Present at the 13th Annual LD Micro Main Event 2020
09 déc. 2020 08h30 HE | Daxor Corporation
NEW YORK, NY, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume...
CVRx® BAROSTIM Therapy Receives CMS Approval for Transitional Pass-Through Payment Status
03 déc. 2020 11h54 HE | CVRx, Inc.
MINNEAPOLIS, Dec. 03, 2020 (GLOBE NEWSWIRE) -- CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announced that the Centers for...
CVRx® Announces New CFO and Acceleration of Barostim Therapy Commercialization Efforts
18 nov. 2020 14h56 HE | CVRx, Inc.
MINNEAPOLIS, Nov. 18, 2020 (GLOBE NEWSWIRE) -- CVRx, Inc., developer of FDA-approved Barostim Therapy to treat chronic heart failure (HF), announced a CFO transition as part of the company’s...
logo-brainhq-hi-res-hori.png
Study: Combining Brain Training and Walking Helps Heart Failure Patients
20 oct. 2020 08h00 HE | Posit Science
SAN FRANCISCO, Oct. 20, 2020 (GLOBE NEWSWIRE) -- A new study from Emory University found a combined therapy of brain training and aerobic exercise improved multiple measures that drive better health...